Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report
<h3>Introduction</h3><p dir="ltr">Polycythemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells. The presence of JAK2 mutation is detected in up to 99% of patients with PV. Pruritis is commonly e...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Published: |
2021
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|